Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Return on Sales (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Return on Sales data on record, last reported at 1.63% in Q4 2025.

  • For Q4 2025, Return on Sales rose 752.0% year-over-year to 1.63%; the TTM value through Dec 2025 reached 1.63%, up 147.0%, while the annual FY2025 figure was 1.63%, 147.0% up from the prior year.
  • Return on Sales reached 1.63% in Q4 2025 per TNGX's latest filing, down from 0.29% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.29% in Q3 2025 and bottomed at 12.2% in Q2 2025.
  • Average Return on Sales over 5 years is 3.99%, with a median of 4.03% recorded in 2022.
  • The widest YoY moves for Return on Sales: up 752bps in 2025, down -1092bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 3.86% in 2021, then decreased by -18bps to 4.53% in 2022, then fell by -25bps to 5.66% in 2023, then crashed by -62bps to 9.15% in 2024, then surged by 82bps to 1.63% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 1.63% in Q4 2025, 0.29% in Q3 2025, and 12.2% in Q2 2025.